APA (7th ed.) Citation

S, D., R, Z., JWF, C., B, T., V, M., Y, L., . . . JK, M. (2026). Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European urology, 89(2), 165. https://doi.org/10.1016/j.eururo.2025.09.4152

Chicago Style (17th ed.) Citation

S, Daneshmand, et al. "Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study." European Urology 89, no. 2 (2026): 165. https://doi.org/10.1016/j.eururo.2025.09.4152.

MLA (9th ed.) Citation

S, Daneshmand, et al. "Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study." European Urology, vol. 89, no. 2, 2026, p. 165, https://doi.org/10.1016/j.eururo.2025.09.4152.